Urate-Lowering Therapy in CKD Stage 3

First-Line Treatment Selection

The American College of Rheumatology strongly recommends allopurinol as the preferred first-line urate-lowering therapy for patients with CKD stage 3, based on moderate certainty of evidence 1, 2, 3
Xanthine oxidase inhibitors (allopurinol or febuxostat) are strongly recommended over probenecid for patients with CKD stage ≥3, based on moderate certainty of evidence 1, 4
Pegloticase is strongly recommended against as first-line therapy due to cost, safety concerns, and favorable benefit-to-harm ratios of other options 1, 5

For allopurinol, the recommended starting dose is low (≤100 mg/day or even lower in CKD) with subsequent dose titration to target serum urate <6 mg/dL, based on moderate certainty of evidence 2, 3
Patients with CKD may require dose titration above 300 mg/day to achieve serum urate targets, despite the traditional concern about dosing limitations, based on moderate certainty of evidence 1, 4
For febuxostat, the recommended starting dose is ≤40 mg/day with subsequent dose titration to target, based on moderate certainty of evidence 3, 6

The risk of allopurinol hypersensitivity syndrome (AHS) is associated with higher starting doses and CKD, emphasizing the importance of starting with low doses, based on moderate certainty of evidence 1, 4

Concomitant anti-inflammatory prophylaxis therapy (colchicine, NSAIDs, or prednisone/prednisolone) is strongly recommended when initiating urate-lowering therapy, based on moderate certainty of evidence 1, 4
Prophylaxis should be continued for 3-6 months after initiating urate-lowering therapy, based on moderate certainty of evidence 1, 4
For patients with CKD stage 3, oral corticosteroids may be the preferred prophylactic agent due to safety considerations 7

For patients who cannot tolerate allopurinol or febuxostat, alternative options should be considered based on individual factors and in consultation with specialists, based on moderate certainty of evidence 5